NICE final yes for Zytiga and Tarceva
07:06 EDT 27 Jun 2012 | InPharm
In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga (abiraterone) is now recommended, in combination with prednisone or prednisolone, as a treatment option for castratio..
Original Article: NICE final yes for Zytiga and Tarceva
More From BioPortfolio on "NICE final yes for Zytiga and Tarceva"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
